Heart failure & cardiomyopathiesCohort study

Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction

ESC Heart FailPublished

  • Cohort of all patients with chronic Chagas disease (CChD) followed at our institution
  • single institution
  • January 2000 to January 2010

Authors' conclusion

Non-dilated left ventricular cardiomyopathy affects one in 10 patients with CHF due to CChD, and the 5-year survival rate is 59%.

Study context

Population
Patients with chronic Chagas disease (CChD) and heart failure with reduced left ventricular ejection fractionpatients with CChD, 21 (10%) had non-dilated left ventricular cardiomyopathy (NDLVC) · NDLVC 21
Participants
215 patients
Exposure
NDLVC vs dilated cardiomyopathy (DCM) secondary to CChD
  • NDLVCn = 21

Main finding

As reported in the abstract

Baseline characteristics of NDLVC group
Groupmean agemalemedian daily dose of metoprololLeft ventricular diastolic diameter (LVDD)Left ventricular ejection fraction (LVEF)Segmental wall motion abnormalities (SWMA)
NDLVC62 ± 9 years12 (57%)100 (62, 5, 125) mg51 ± 29 mm39 ± 6.4%12 (57%)

Observational data: associations, not effects.

Further findings

Predictor of all-cause mortality for patients with NDLVC (Cox regression)

Comparisonhazard ratio (95% CI)P value
Beta-blocker therapy · only independent predictor0.16 (0.04–0.68)P = 0.01
OutcomeNDLVCDCMEstimateP value
Kaplan-Meier survival estimates at 12, 24, 36, 48, and 60 months · 60-month follow-up71%, 71%, 59%, 59%, and 59%77%, 61%, 49%, 38%, and 30%P = 0.04
All-cause mortality in NDLVC · Mean follow-up 50.8 ± 3.8 months
43% · 9 of 21

Original publication

Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction. ESC Heart Fail. Published 13 January 2026. doi:10.1093/eschf/xvag020

Summarised from the published abstract; every number is checked against it